Cardiotoxicity News
The Feed Reader Bot (@TheFeedReaderBot) will send messages in this channel
17 December 2019
15:08
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
15:08
In reply to this message
pubmed: tutte cardiotoxicity...
The Australia and New Zealand Cardio-Oncology Registry (ACOR): evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients.
Related Articles
The Australia and New Zealand Cardio-Oncology Registry (ACOR): evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients.
Intern Med J. 2019 Dec 16;:
Authors: Lapirow D, La Gerche A, Toro C, Masango E, Costello B, Porello E, Ludlow L, Marshall G, Trahair T, Mateos M, Lewin J, Byrne J, Boutros R, Manudhane R, Heath J, Ayer J, Gabriel M, Walwyn T, Saundankar J, Forsey J, Le H, Mason K, Celermajer D, Downie P, Walker R, Holland L, Martin M, McLeman L, Diamond Y, Marcocci M, Donath S, Cheung M, Elliott DA, Conyers R
Abstract
Cancer therapy related cardiac dysfunction (CTRCD) is an area of increasing focus, particularly during the survivorship period, for paediatric, adolescent and adult cancer survivors. With the advent of immunotherapy and targeted therapy, there is a new set of mechanisms from which paediatric and young adult patients with cancer may suffer cardiovascular injury. Furthermore, cardiovascular disease is the leading cause of morbidity and mortality in the survivorship period. The recently established Australian Cardio-Oncology Registry (ACOR) is the largest and only population-based cardiotoxicity database of paediatric and adolescent and young adult (AYA) oncology patients in the world, and the first paediatric registry that will document cardiotoxicity caused by chemotherapy and novel targeted therapies using a prospective approach. The database is designed for comprehensive data collection and evaluation of the Australian practice in terms of diagnosis and management of CTRCD. Using the ACOR registry critical clinical information will be collected regarding predisposing factors for the development of CTRCD, the rate of subclinical LV dysfunction and transition to overt heart failure, further research into protectant molecules against cardiac dysfunction and aid in the discovery of which genetic variants predispose to CTRCD. A health economic arm of the study will assess the cost/benefit of both the registry and cardio-oncology clinical implementation. Finally, an imaging arm will establish if exercise magnetic resonance imaging (CMR) and VO2 max testing is a more sensitive predictor of cardiac reserve in paediatric and AYA oncology patients exposed to cardiac toxic therapies. This article is protected by copyright. All rights reserved.
PMID: 31841257 [PubMed - as supplied by publisher]
18 December 2019
16:04
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
16:04
In reply to this message
pubmed: tutte cardiotoxicity...
The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review.
Related Articles
The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review.
Life Sci. 2019 Dec 13;:117173
Authors: Najafi M, Shayesteh MRH, Mortezaee K, Farhood B, Haghi-Aminjan H
Abstract
PURPOSE: Doxorubicin, as an effective chemotherapeutic drug, is commonly used for combating various solid and hematological tumors. However, doxorubicin-induced cardiotoxicity is considered as a serious adverse effect, and it limits the clinical use of this chemotherapeutic drug. The use of melatonin can lead to a decrease in the cardiotoxic effect induced by doxorubicin. The aim of this review was to evaluate the potential role of melatonin in the prevention of doxorubicin-induced cardiotoxicity.
METHODS: This review was conducted by a full systematic search strategy based on PRISMA guidelines for the identification of relevant literature in the electronic databases of PubMed, Web of Science, Embase, and Scopus up to January 2019 using search terms in the titles and abstracts. 286 articles were screened in accordance with our inclusion and exclusion criteria. Finally, 28 articles were selected in this systematic review.
RESULTS: The findings demonstrated that doxorubicin-treated groups had increased mortality, decreased body weight and heart weight, and increased ascites compared to the control groups; the co-administration of melatonin revealed an opposite pattern compared to the doxorubicin-treated groups. Also, this chemotherapeutic agent can lead to biochemical and histopathological changes; as for most of the cases, these alterations were reversed near to normal levels (control groups) by melatonin co-administration. Melatonin exerts these protection effects through mechanisms of anti-oxidant, anti-apoptosis, anti-inflammatory, and mitochondrial function.
CONCLUSION: The results of this systematic review indicated that co-administration of melatonin ameliorates the doxorubicin-induced cardiotoxicity.
PMID: 31843530 [PubMed - as supplied by publisher]
16:04
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
16:04
In reply to this message
pubmed: tutte cardiotoxicity...
Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again.
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles
Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again.
Comments
Post a Comment
اكتب تعليق حول الموضوع